PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1

Phase 1, open-label trial of PGT121 and VRC07-523LS in human immunodeficiency virus type 1 infection (HIV-1) (4 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Proportion of infants with at least one Grade 3 or higher Adverse Event (AE) at 24 weeks, Proportion of infants with at least one Grade 3 or higher AE assessed as related to study product at 24 weeks and 5 more. Started Jan 2026; status: recruiting.